EUROFINS SCIENT (ERFSF)
(Delayed Data from OTC)
$78.11 USD
+0.01 (0.01%)
Updated Aug 4, 2025 03:42 PM ET
2-Buy of 5 2
B Value A Growth C Momentum A VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ERFSF 78.11 +0.01(0.01%)
Will ERFSF be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ERFSF based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ERFSF
Has BioNTech (BNTX) Outpaced Other Medical Stocks This Year?
Is Encompass Health (EHC) Stock Outpacing Its Medical Peers This Year?
ERFSF: What are Zacks experts saying now?
Zacks Private Portfolio Services
EUROFINS SCIENT (ERFSF) Upgraded to Strong Buy: Here's Why
Is EUROFINS SCIENT (ERFSF) Outperforming Other Medical Stocks This Year?
EUROFINS SCIENT (ERFSF) Upgraded to Buy: Here's What You Should Know
Other News for ERFSF
Eurofins Scientific price target raised by EUR 8 at Berenberg
Eurofins Scientific price target raised by EUR 10.40 at Citi
Eurofins Scientific SE (ERFSF) (H1 2025) Earnings Call Highlights: Strong Revenue and EPS ...
Half Year 2025 Eurofins Scientific SE Earnings Call Transcript
Longleaf Partners Global Fund Q2 2025 Commentary